October 22, 2018

Mark R. Baker
Chief Executive Officer
Progenics Pharmaceuticals, Inc.
One World Trade Center
New York, New York 10007

       Re: Progenics Pharmaceuticals, Inc.
           Registration Statement on Form S-3
           Filed October 12, 2018
           File No. 333-227805

Dear Mr. Baker:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Irene Paik at 202-551-6553 with any questions.



                                                            Sincerely,

                                                            Division of
Corporation Finance
                                                            Office of
Healthcare & Insurance
cc:    Tobias L. Knapp - O'Melveny & Myers LLP